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Background
Non-chemotherapy related, drug-induced agranulocytosis
is a rare idiosyncratic reaction, which may be fatal. Along
with betalactames, the analgesic metamizole is reported to
occasionally cause agranulocytosis. The disease results in a
severe reduction of granulocytes rendering affected
patients susceptible to bacterial and fungal infections. The
pathogenesis of drug-induced agranulocytosis is complex
as non-immune (mainly toxic) and immune mechanisms
might be involved.
Aim
The identification and characterization of metamizole-
specific T cells in patients with drug-induced agranulocy-
tosis by generating metamizole-specific T cell lines.
Methods
PBMCs from metamizole-allergic and metamizole-tolerant
subjects were induced with 100ug/ml metamizole. Cultures
were supplemented with IL-2 and were restimulated every
14 days. Drug-specific cell activation was determined by
flow cytometry after a 6h restimulation phase.
Results
After two restimulation rounds, metamizole-specific
T cells were identified in a metamizole-allergic and in a
metamizole-tolerant individual. In both cases, CD8+
T cells but no CD4+ cells reacted to the drug. Reactive
cells secreted IFN and upregulated CD107a upon drug
exposure. Interestingly, T cells were activated exclusively
by metamizole in solution. Autologous antigen presenting
cells incubated overnight in 100ug/ml metamizole prior to
restimulation failed to activate CD8+ T cells. Furthermore,
metamizole-specific T cells from both donors, allergic and
tolerant, were self-reactive, i.e. reacted to the drug even in
the absence of antigen presenting cells.
Conclusion
The observed CD8+ T cell reactivity which was exclusively
restricted to metamizole in solution supports a T cell acti-
vation according to the p-i concept (pharmacological
interactions with immune receptors). Other hypersensitiv-
ity reactions underlying this concept revealed the crucial
role of particular HLA class I molecules (e.g. HLA-B*57:01
in abacavir hypersensitivity). We therefore plan to type the
study participants for their HLA class I expression in
order to identify HLA molecules potentially involved in
metamizole-induced agranulocytosis. This screening pro-
cess will be supported by in silico modeling of metamizole
binding to a panel of common HLA class I molecules.
Furthermore, we plan to characterize metamizole-specific
T cells in regards to their cytotoxic potential, i.e their
expression of Granzyme B, Granulysin, perforin and FasL
upon drug exposure.
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